Company intelligence / Profile preview

Cosmo Korea

Ownership: Private
Development stage: Other

Overview

Cosmo Korea is the South Korean subsidiary of Cosmo Pharmaceuticals, a Swiss-based specialty pharmaceutical company focused on gastroenterology and dermatology. The company manages the clinical development and commercialization of Cosmo's global portfolio within the Korean and broader Asian markets. Its product lineup includes Winlevi, a first-in-class topical androgen receptor inhibitor for acne, and various treatments for inflammatory bowel diseases. Cosmo Korea also promotes innovative medical devices such as Eleview for endoscopic visualization and the AI-powered GI Genius system for polyp detection. The entity serves as a strategic hub for expanding the parent company's footprint in the Asia-Pacific region.

Therapeutic areas: OncologyInfectious DiseasesDermatologyGastroenterology
Modalities: Small moleculeDevice
Industry: Biotech

Partnerships

Medtronic

Beyond the preview

Go deeper on Cosmo Korea.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cosmo Korea.

Explore the full profile